Background-A number of single gene defects have been identified in patients with isolated or nonsyndromic congenital heart defects (CHDs). However, due to significant genetic heterogeneity, candidate gene approaches have had limited success in finding high-risk alleles in most cases. The purpose of this study was to use exome sequencing to identify high-risk gene variants in a family with highly penetrant pleiotropic CHD. Methods and Results-DNA samples from 2 members of a family with diverse CHD were analyzed by exome sequencing.
O ver the past decade, a number of single gene defects have been identified in patients with isolated or nonsyndromic congenital heart defects (CHDs). 1 The first gene to be identified was NKX2.5, identified by linkage analysis in families with atrial septal defects (ASDs) associated with atrioventricular conduction delay. 2 Subsequently, mutations in GATA4 were identified in families with isolated ASDs. 3 More recently, candidate gene screening has identified variations in GATA6 in patients with truncus arteriosus, 4 whereas variations in MYH6, 5,6 TBX5 7 and TBX20 8 have been discovered in patients with septal and valve defects. Using a linkage approach, Garg and colleagues 9 identified nonsense and frameshift mutations in NOTCH1 in 2 families with a variety of left ventricular outflow tract malformations ranging from bicuspid aortic valve (BAV) to hypoplastic left heart syndrome. Subsequently missense variations in NOTCH1 have been identified in patients with BAV. 10, 11 We recently identified LPP as a candidate gene for tetralogy of Fallot. 12 
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These studies highlight the fact that screening high-risk kindreds with multiple affected family members has led to the discovery of pathogenic gene variants. Although candidate gene screening has identified numerous disease-causing variants in many conditions, it has had limited success in CHD, probably because many genes are involved in cardiac development (genetic heterogeneity) and low-risk alleles may be found in introns or regulatory regions. Therefore, new approaches are required to identify genetic variants in sporadic cases or probands of small families. One possibility is whole genome sequencing, but this is currently cost-prohibitive for many laboratories. At present, an alternative method is whole exome sequencing, which admittedly provides less coverage of the genome but at significantly lower cost.
We describe whole exome sequencing analysis of a family with a preponderance of secundum ASD but also other cardiac defects, including ventricular septal defect, coarctation of the aorta (CoA), aortic stenosis, and BAV.
Methods

Patient Enrollment and Phenotyping
With University of Utah Institutional Review Board approval, members of a kindred with CHD were enrolled in the University of Utah Pediatric Cardiology Genotype-Phenotype Core and blood samples collected for DNA isolation. Medical records were reviewed for demographic and clinical data.
DNA Isolation and Exome Sequencing
DNA was isolated from peripheral blood samples using a Gentra Autopure LS (Qiagen, Valencia, CA). DNA samples were analyzed by agarose gel electrophoresis to confirm the integrity of the DNA and quantitated using a Nanodrop.
Whole Exome Sequencing
Exome sequencing (library construction, capture, and sequencing) was carried out on 2 DNA samples (from Patients III.3 and III.7) at the genomic service laboratory at HudsonAlpha Institute for Biotechnology (Huntsville, AL). Briefly, 3 to 5 g of genomic DNA was fragmented by sonication to achieve a mean size of 200 bp. The sonicated DNA ends were repaired using T4 DNA polymerase and Klenow fragment. A single A base was added to the 3Ј end of repaired DNA fragments using Klenow fragment. The resulting end-repaired DNA with a single A-base overhang was ligated to the Illumina paired-end adaptors that have a T-base overhang at their 3Ј ends. After ligation, the samples were assessed for size distribution on the Agilent Bioanalyzer and then amplified by 6 cycles of polymerase chain reaction (PCR) to maintain complexity and avoid bias caused by amplification. Five hundred nanograms of amplified library was hybridized to the NimbleGen SeqCap EZ Exome Library Version 2 for enrichment using the manufacturer's protocols. After hybridization and elution, enriched library was PCR-amplified for 12 cycles and again assessed for appropriate size distribution (300 -400 bp) using the Agilent Bioanalyzer. Appropriate amounts of the library were loaded onto the Illumina flowcell on the Illumina HiSeq 2000 instrument. After cluster generation, 50 bp-paired end sequencing was performed using the standard Illumina protocols.
Exome Sequencing Data Analysis
Raw sequencing data for each individual were aligned to the reference human genome (GRCh37/hg19, downloaded from http:// genome.ucsc.edu) with 2 alignment programs, Burrows-Wheeler Alignment Tool 13 and Novoalign (www.novocraft.com/). Average read depth across the whole exome for each sample achieved 80ϫ coverage. Using the software package SAMtools, 14 the aligned sequencing reads were converted and merged to sorted and indexed BAM files. The SAMtools utilities mpileup and bcftools were implemented to call sequence variants. Functional annotation of the genetic variants was preformed with the ANNOVAR software 15 with respect to locations (exonic, intronic, splice site, 5Ј UTR, 3Ј UTR, upstream, downstream, or intergenic) and then by exonic functions (nonsynonymous, synonymous, stop, frameshift insertion/deletion, etc) using the "known genes" track from UCSC Genome Browser (www.genome.ucsc.edu/). ANNOVAR was used to annotate variants not previously reported in the 1000 Genome Project (Phase1 All-Sites [2011_05]) or dbSNP databases 16 (dbSNP build 132) or present with a minor allele frequency (Ͼ1%) in whites. To predict deleterious effects of nonsynonymous amino acid changes, ANNOVAR uses various functional annotation algorithms such as SIFT, 17 Poly-Phen2, 18 and MutationTaster. 19 The sequence data were also analyzed using Golden Helix's high-performance analytic software SNP and Variation Suite (www.golden.helix.com). The sample data were filtered to include variants that were present in both samples and exclude variants present in exome data sets (using the NimbleGen SeqCap EZ Exome Library) from 10 unrelated individuals with different phenotypes, including 2 patients with hypoplastic left heart syndrome, to eliminate common variants and sequencing artifacts.
Integrative Genome Viewer 20 (www.broadinstitute.org/igv/), an efficient and intuitive visualization tool, was used to examine aligned sequence reads and genome annotation files as well as assess coverage and the overall quality of the aligned sequence reads. In addition, the Variant Annotation, Analysis and Search Tool 21, 22 was used to carry out a probabilistic search using amino acid substitution and aggregative approaches to variant prioritization, combining elements of both into a single unified likelihood framework to identify damaged genes and their disease-causing variants in personal genome sequences.
Validation of Variants Identified by Exome Sequencing
PCR primers were designed to amplify variants using Primer3Plus (www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) and used to amplify DNA from 1 of the patient samples analyzed by exome sequencing (PCR primers and conditions are described in Supplemental Table I ). The PCR product was purified by treating with 4 L of Exo-SAP-IT (USB, Cleveland, OH) at 37°C for 2 hours and 80°C for 15 minutes. An aliquot of DNA was analyzed by agarose gel electrophoresis and then submitted to the University of Utah DNA sequencing core for analysis.
Once a variant was confirmed, all available family members were screened to determine variant segregation. All patient DNA samples (10 ng per sample) were amplified by PCR in duplicate along with negative (water) controls using Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA). After amplification, 0.5 L of LC Green I (Idaho Technologies, Salt Lake City, UT) and 1.1 L of dimethyl sulfoxide were added to each 10 L reaction. The mix was heated at 95°C for 5 minutes and then cooled to 4°C. The PCR products were analyzed on a Lightscanner (Idaho Technologies) according to the manufacturer's instructions. The plates were heated at 0.1°C/s, and fluorescence was collected from 70°C to 98°C. Melting curves were analyzed using the Call-IT software (Idaho Technologies). Briefly, after exponential background subtraction, melting curves were normalized between 0% and 100%. Normalized and temperatureoverlaid curves were viewed on difference plots to magnify variations in melting curve shape. Difference plots were generated by subtracting each curve from the mean wild-type curve, defined as the most common genotype. Selected samples from each analysis as well as all samples for variants that showed significant segregation were analyzed by DNA sequencing, following Exo-SAP purification, as described previously, to confirm the Lightscanner results.
Results
Clinical Characteristics of Family K100165
During the routine clinical evaluation of Patient III.9 (Figure) , an extensive family history of CHD was elicited ( Table  1 ). The first known individual in the family with CHD was the grandparent (Patient I.2) who had a secundum ASD diagnosed as an adult and underwent surgical closure of the defect. This patient died before ascertainment of the family. The grandparents had 6 children, 1 of whom (Patient II.4) was also found to have a secundum ASD and underwent surgical closure of the defect as a teenager. There is no known CHD in the remaining 5 children; however, all except the youngest (II.12) have descendants with CHD ( Figure) . Patient III.2 had a secundum ASD that closed spontaneously. Patient III.3 has a small secundum ASD that has not required closure. Patient III.5 is unaffected but has 3 children with CHD: Patient IV.1 has Shone complex and underwent surgery to repair CoA, aortic stenosis, mitral stenosis, and removal of a subaortic membrane; Patient IV.2 was born with a secundum ASD as well as a BAV and CoA and underwent surgical correction of the ASD and CoA; Patient IV.3 is an infant who was recently diagnosed with a secundum ASD. Patient III.6, the sibling of Patient III.5, was born with BAV, CoA, and a ventricular septal defect. Initially this patient underwent CoA repair and placement of a pulmonary artery band but later developed subaortic membrane and underwent surgical resection of the subaortic membrane, ventricular septal defect closure, and removal of the pulmonary artery band. As a teenager, Patient III.6 was noted to have an aneurysm of the thoracic aorta at the coarctation repair site. The aneurysm was surgically resected and an interposition graft placed. Patient III.6 was evaluated by a connective tissue disease specialist who felt that the thoracic aneurysm was a surgical complication rather than a manifestation of connective tissue disease. Patient III.7 had a secundum ASD that closed spontaneously. Patient III.8 had a secundum ASD that required surgical closure. Patient III.9 was born with a secundum ASD and ventricular septal defect and underwent surgical repair of both defects in the first year of life. At age 19 years, Patient III.9 experienced several weeks of chest and abdominal pain and was found to
Family K100165. The gender of family members is not indicated. Black symbols represent patients with ASD or complex phenotypes that include ASD. Gray symbols represent patients with CHD but without ASD. Patient III.11 was diagnosed with a murmur as a child but has not had an echocardiogram to rule out the presence of an ASD and has not experienced any cardiac-related health issues. ASD indicates atrial septal defect; CHD, congenital heart defect; CoA, coarctation of the aorta; VSD, ventricular septal defect; BAV, bicuspid aortic valve; AS, aortic stenosis. have an aortic dissection extending from the distal ascending aorta to the abdominal aorta. The dissection was unusual because there was no history of aortic arch surgery and no significant aortic dilation noted before aortic dissection. Patient III.9 was evaluated by a connective tissue disease specialist who documented pectus excavatum and retrognathia (also noted in the patient's mother). Pertinent negative findings included a normally shaped cranium, normal vision, normal palate and uvula, normal height/arm span/finger length, no joint hypermobility, and no striae or increased skin lucency. The patient's facies was not felt to be consistent with Type IV Ehlers-Danlos syndrome. To rule out Loeys-Dietz syndrome, mutational analysis of TGF␤R1 and TGF␤R2 was performed but no mutations were found. However, variants in genes associated with thoracic aortic aneurysm and/or aortic dissection (eg, ACTA2 and MYH11) were not screened. Patient III.10 was born with BAV and CoA and underwent CoA repair early in life. Patient III.11 was noted to have a murmur as a teenager but never underwent echocardiographic evaluation. Interestingly, the spouses of II.6 and II.9 have at least 1 distant family member with left ventricular outflow tract malformations. This raises the possibility that their offspring may have inherited genetic susceptibilities for CHD from these spouses.
Exome Sequence Analysis and Segregation of Variants
Exome analysis was performed on DNA samples from Patients III.3 and III.7. Even after filtering, Ͼ2000 variants (including single nucleotide substitutions and indels) were shared by these 2 individuals. Of these, 46 were nonsynonymous, 3 were predicted to alter splicing, and 6 resulted in a frameshift. We reasoned that the variant associated with disease in this family was likely to be novel and predicted by VAAST to be functionally important. Furthermore, we reasoned that the affected genes would have a probable role in cardiac development or structure/function. This reduced the number of candidate variants to 18 ( Table 2 ). Analysis of the remainder of the family showed that none of these variants completely segregated with CHD (Table 3 ). For example, Myh6 Ala230Pro, previously identified in a patient with tricuspid atresia and large secundum ASD, 5 was present 10 of the 11 affected individuals; it was not carried by III.2. In addition, the variant was not detected in the spouse of the founder suggesting it was inherited from the affected founder. Another example, UVRAG T641I, was also apparently inherited from the founder but was only detected in 5 of the 10 affected patients screened, including III.2 ( Table 3 ).
Analysis of ASD Candidate Genes in Patient III.2
Patient III.2 did not carry the Myh6 Ala230Pro variant. For this individual we analyzed the coding sequences of the known genes associated with ASD (GATA4, NKX2.5, TBX5, TBX20, and MYH6) by direct DNA sequencing. Two novel heterozygous synonymous variants were identified (NKX2-5 1c.53CϾT: p.Phe51 and MYH6 c.4140CϾT: p.Asp1380); neither variant was predicted to alter mRNA splicing.
Discussion
This study represents the first reported exome sequence analysis of a family with diverse CHD. The predominant phenotype in this family is secundum ASD. However, there is significant variability with many family members having a form of left ventricular outflow tract obstruction. Therefore, for the exome analysis, we selected DNA from 2 individuals in branches of the family in which the phenotype was highly penetrant and predominantly affected the atrial septum. A significant number of shared novel variants were identified in these affected individuals, although none of the likely pathogenic variants completely segregated, highlighting the complexity of identifying CHD causing gene variants.
Based on our findings and previous experimental data, we suggest that the Myh6 Ala230Pro variant likely plays a major role in the development of CHD in this family. Alanine 230 is located in the motor domain of Myh6 and was previously identified in a patient diagnosed in infancy with tricuspid atresia, valvular and supravalvular pulmonary stenosis, hypoplastic right ventricle, and large secundum ASD. 5 In that family, the variant was inherited from the father, who did not have CHD but rather left ventricular hypertrophy. The variant was also carried by an unaffected sister. The alanine residue is conserved in all muscle myosins and is located in a region that is responsible for the kinetic coupling between nucleotide binding and the variation in affinity for actin during the ATPase cycle. 23 Granados-Riveron and colleagues 5 have shown that this variant likely abolishes a hydrogen bond between the alanine at position 230 and another alanine residue at position 227 and introduces a steric clash between the mutant proline residue and Ala227. They have also shown that the Ala230Pro substitution disrupts assembly of myosin molecules into higher-order structures in vitro. 5 Furthermore, involvement of ␣ myosin heavy chain (encoded by MYH6) in atrial septation is supported by 2 reports of geneknockdown in chick embryos. 6, 24 Although this variant appears highly damaging, phenotypically normal individuals in our pedigree and in the pedigree of Granados-Riveron et al 5 can carry the variant, suggesting reduced expressivity. In addition, there is evidence for phenotypic variability among patients with Myh6 Ala230Pro.
MYH6 variants have been identified in patients with a variety of CHD phenotypes including transposition of the great arteries, tricuspid atresia, patent foramen ovale, septal dyskenesis, truncus arterioisus, subaortic ridge, and dilated inferior vena cava. 5 In our pedigree, we too observe CHD pleiotropy with defects that include ASD (I.2, II.4, III.3, III.7, III.8, III.9, IV.2, IV.3), CoA (III.6, III.10, IV.1, IV.2), BAV (III.5, III.10, IV.2), aortic stenosis and mitral stenosis (IV.1), and ventricular septal defect (III.6 and III.9). Two patients also developed aortic arch pathology later in life. In the case of Patient III.6, an aortic aneurysm occurred at the site of coarctation repair, whereas Patient III.9 had spontaneous aortic dissection without a history of aortic surgery or significant aortic dilation. Although Myh6 expression has not been reported in the outflow tract or aorta, studies of a zebrafish myh6 mutant found altered myocyte morphology and impaired atrial function with decreased blood flow 25 that could explain more widespread disturbances in cardiac development. Although the Myh6 Ala230Pro variant may be the ASD cause of the left ventricular outflow tract anomalies, the phenotypic variation could also be due to inheritance of other variants. In particular both II.5 and II.10 are members of families with a history of left ventricular outflow tract malformations. Thus, the offspring in these arms of the pedigree, which have the greatest phenotypic variation, could have inherited variants from parents who married into the family. It is also possible that other variants could modulate phenotype. For example, the Dusp6 variant p.Arg85Cys detected in our exome analysis has not previously been reported in online databases and was not detected in 288 ethnicity-matched control subjects. Dusp6 is expressed in the heart and null mice have large hearts due to overactivation of ERK1/2. 26 Interestingly, other pathways involving Erk1/2 activation have been implicated in CHD. For example, MEK1 and MEK2 activate Erk1/2 and gain of function MEK2 mutations cause cardiofaciocutaneous syndrome, a component of which is ASD. Of note, a number of members of this family had aortic pathology (coarctation or dissection). Given that MYH6 is not known to be expressed in the aorta, it is likely that additional genetic variants affecting outflow tract development explain the variation of phenotypes in the family. Given the large number of candidate genes, sequencing of all family members would be necessary to identify all the phenotypic modifiers. However, it should also be noted that exome sequencing will miss most intronic/regulatory variants that could have a role in modifying the phenotype. For example, recent work demonstrates that certain haplotypes at the ERBB4 locus mark noncoding susceptibilities to this class of CHD. 27 In another report, ISL1 haplotypes were found to be associated with a risk for a broader spectrum of CHD. 28 Some combination of these factors, the definition of which being beyond the scope of this report, may explain the phenotypic variability of expression in the Ala230Pro carriers. Similarly, copy number variants have been associated with some forms of CHD, 29 although not with ASD. Copy number variant analysis was not clinically indicated in this family and was not done as part of our research study. Therefore, transmission of a copy number variant cannot be ruled out as an underlying contributor to CHD in this family. Future application of next-generation sequencing, particularly whole genome sequencing that captures noncoding single nucleotide polymorphisms, may shed light on these issues in this family and in other cases of CHD.
Patient III.2 does not carry the Myh6 Ala230Pro variant. This raises the question whether this variant is the cause of CHD in this family. This patient had 1 of the mildest phenotypes with his ASD closing spontaneously by adulthood. Thus, a possibility is that this patient represents a sporadic case with disparate genetic susceptibilities. At present, the genetic etiology of this case is unknown as no pathogenic variants were identified in ASD candidate genes, GATA4, NKX2.5, TBX5, TBX20, and MYH6.
This study highlights the fact that, even in familial congenital heart disease, the underlying genetic etiology can be complex. In addition, the use of next-generation sequencing approaches to identify disease/defect-causing genetic variants will be associated with significant bioinformatic challenges for the foreseeable future. However, as next-generation sequencing becomes the method of choice for identifying the genetic causes of CHD, it will continue to be important to incorporate information provided by family analysis.
